Pharmaust Limited (AU:PAA) has released an update.
PharmAust Limited, a clinical-stage biotech company focused on developing treatments for neurodegenerative diseases, has issued 200,000 new ordinary shares following the exercise of unlisted options at 10 cents each, without requiring disclosure to investors. The company, which adheres to the Corporations Act compliance, is advancing its repurposed drug, monepantel (MPL), through clinical trials for ALS treatment with potential FDA approval anticipated in 2026.
For further insights into AU:PAA stock, check out TipRanks’ Stock Analysis page.
